BRAF and melanoma: Inhibition of mutated BRAF kinase is a well-validated approach for cancer therapy and three selective small molecular BRAF inhibitors, that is, vemurafenib (1,Figure 1), encorafenib (2), and dabrafenib (3) have achieved significant clinical benefits in patients of melanoma and colon cancer harboring BRAF mutations (Bollag et al., 2010; Rheault et al., 2013; Holderfield et al., 2014; Karoulia et al., 2017; Koelblinger et al., 2018).